Jun Chen

To the Editor, We read with great interest the target trial emulation by Wu et al. [1], which provides timely Chinese real-world evidence that GLP-1 receptor agonist initiation may promote clinically meaningful weight loss among suboptimal responders after metabolic bariatric surgery. This work is particularly relevant as incretin-based therapies are increasingly extending beyond primary obesity management into post-bariatric rescue and maintenance care.

Subject areas Health sciences Medicine Medical specialty Internal medicine Neurology Introduction Parkinson’s disease (PD) is a common neurodegenerative disorder with a global prevalence of over 6 million.1 Motor symptoms are typical features of PD, such as tremor, rigidity, bradykinesia, and postural instability.2 However, increasing evidence indicates that health-related issues caused by non-motor symptoms are more significant.3 PD-mild cognitive impairment (PD-MCI) refers to the gradual...